IP Library Granted Patent US 11,267,855
Granted Patent B2
US 11,267,855 · App. 16/356,872 · Granted Mar 8, 2022

Engineered FGF1 and FGF2 compositions and methods of use thereof

Inventors: Suresh Kumar Thallapuranam (Fayetteville, AR); Shilpi Agarwal (Fayetteville, AR); Ravi Kumar Gundampati (Fayetteville, AR); Srinivas Jayanthi (Fayetteville, AR); Tengjiao Wang (Fayetteville, AR); Jake Jones (Fayetteville, AR); Olivia Kolenc (Fayetteville, AR); Ngoc Lam (Fayetteville, AR); Isabelle Niyonshuti (Fayetteville, AR); Kartik Balachandran (Fayetteville, AR); Kyle Quinn (Fayetteville, AR); Jingyi Chen (Fayetteville, AR)
Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
C07K14/501A61K9/06C07K14/503A61K38/00A61K38/1825C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,267,855
App. No.
16/356,872
Granted
Mar 8, 2022
Kind
B2
Abstract

Engineered FGF1 and FGF2 polypeptides, polynucleotides encoding these polypeptides and DNA constructs, vectors and compositions including these engineered polypeptides are provided herein. The engineered FGF1 and FGF2 polypeptides are more stable than their wild-type counterparts and may be more effective at treating a variety of conditions that FGF1 and FGF2 are useful for treating such as wound healing.

Claims (13)

1. A FGF1 polypeptide comprising at least 90% sequence identity to SEQ ID NO: 1 and comprising amino acid substitutions at least at residues Q41, S48, H94, K113, and R123 of SEQ ID NO: 1, or a functional fragment of the FGF1 polypeptide thereof

wherein the substitution at residue Q41 is selected from the group consisting of Q41P, Q41F, Q41M, Q41Y, Q41W, Q41I, Q41L, Q41V, and Q41A;

wherein the substitution at residue S48 is selected from the group consisting of S48L, S48A, S48V, S48P, S48T, S48M, S48I, S48F, S48Y, and S48W;

wherein the substitution at residue H94 is selected from the group consisting of H94S, H94T, H94K, H94R, and H94Y;

wherein the substitution at residue K113 is selected from the group consisting of K113N, K113Q, K113S, K113T, K113R, and K113Y;

and wherein the substitution at residue R123 is selected from the group consisting of R123E and R123D.

2. The FGF1 polypeptide of claim 1 , wherein the FGF1 polypeptide comprises the substitutions Q41P, S48L, H94S, K113N, and R123E.

3. The FGF1 polypeptide of claim 1 , wherein the FGF1 polypeptide comprises SEQ ID NO: 2.

4. A fusion protein comprising the FGF1 polypeptide of claim 1 and a membrane permeable peptide.

5. A pharmaceutical composition comprising the FGF1 polypeptide of claim 1 and a pharmaceutical carrier.

6. A hydrogel comprising the FGF1 polypeptide of claim 1 .

7. A method of promoting wound healing in a subject in need thereof comprising administering a therapeutically effective amount of the FGF1 polypeptide of claim 1 to the subject.

8. The method of claim 7 , wherein the subject is a mammal.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE SECOND INVENTOR'S NAME PREVIOUSLY RECORDED AT REEL: 048881 FRAME: 0069. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Dec 13, 2021
From: THALLAPURANAM, SURESH KUMAR; AGRAWAL, SHILPI; GUNDAMPATI, RAVI KUMAR; JAYANTHI, SRINIVAS; WANG, TENGJIAO; JONES, JAKE; KOLENC, OLIVIA; LAM, NGOC; NIYONSHUTI, ISABELLE; BALACHANDRAN, KARTIK; QUIN, KYLE; CHEN, JINGYI
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
Reel/Frame 058962/0968 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2019
From: THALLAPURANAM, SURESH KUMAR; AGARWAL, SHILPI; GUNDAMPATI, RAVI KUMAR; JAYANTHI, SRINIVAS; WANG, TENGJIAO; JONES, JAKE; KOLENC, OLIVIA; LAM, NGOC; NIYONSHUTI, ISABELLE; BALACHANDRAN, KARTIK; QUIN, KYLE; CHEN, JINGYI
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
Reel/Frame 048881/0069 →
Continuity (2)
Provisional Application 62644076 · Mar 16, 2018
Related Publication 20190284252A1 · Sep 19, 2019